Vivimed Labs share news, announcements and annual reports
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.64down ₹0.11 (1.91%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹5.75.
29 Oct: open ₹5.65, high ₹5.65, low ₹5.64
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹47 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,884
Vivimed Labs board and management
20 filed, newest first.
May 2024
20 May · Management
20 May · Management
Feb 2024
Jan 2022
Oct 2021
May 2020
Jan 2020
Apr 2016
Dec 2015
Mar 2015
May 2013
22 May · Management
Board of Directors, vide a Circular Resolution dated May 15, 2013 has Appointed Dr. V. Peesapati as an Additional Director (Non Executive & Independent) of the Company with effect from May 22, 2013.
Jun 2010
29 Jun · Management
Board of Directors of the Company has appointed Mr. Nixon Patel as an Additional Director of the Company with effect from June 28, 2010. Mr. Nixon Patel has been appointed as an Independent Director on the Board.
May 2010
31 May · Management
At the Board meeting of the Company held on May 29, 2010, the Board has approved the appointment of Mr. Fahim Aslam Khan as Company Secretary and Compliance Officer of the Company.
Aug 2009
14 Aug · Management
Mr. Y Krishna has been appointed as an Additional Director on the Board of Vivimed Labs Limited with effect from June 30, 2009 in the Board Meeting of the Company held on June 30, 2009.
Dec 2008
23 Dec · Management
Dr. Raj Barathur who has been rendering his services as a Director on the Board of Vivimed Labs Limited has resigned to his directorship with effect from November 27, 2008.
Aug 2008
13 Aug · Management
Mr. Chanakya Chandra Reddy P has been appointed as the Secretary cum Compliance Officer of the Company with effect from July 07,2008.
Jan 2008
24 Jan · Management
Meeting of the BoDs of the Company has been held on January 23, 2008 whereat the Board has decided among other things : (1) Appointment of Dr. V. Manohar Rao, who was Chairman & Managing Director of VVS Pharmaceuticals & Chemicals Pvt Ltd which has been merged into the Company with effect from 01.04.2006 and who is also a Founder/ Promoter Director of both the Companies, is appointed as Executive Chairman of the Company with immediate effect on such terms and conditions to be decided by the Board of Directors, as desired by all the Directors of the Company, to avail the benefit of his long and valuable experience in establishing and running industrial units. Dr. V Manohar Rao is father of Mr. Santosh Varalwar. (2) Appointment of Additional Directors to the Board.